Protein binding of NADH on chemical preconditioning.
Chemical preconditioning, an emerging neuroprotective strategy described in recent years, results in preserved energy metabolism during hypoxia via yet unknown mechanisms. The hypoxic increase of NADH content is attenuated by preconditioning. The goal of the present study was to investigate whether attenuation of the hypoxic NADH increase is due to a shift between free and protein-bound NADH. NADH in solution has a fluorescence maximum at 469.2 nm. In untreated mouse hippocampal slices, lambda(control onset) is 456.2 +/- 5.3 nm in CA1 (mean +/- SD; p < 0.01 vs. solution) and 454.6 +/- 6.1 nm in CA3 [p < 0.01 vs. solution, not significant (NS) to lambda(control onset) in CA1]. In slices prepared from animals pretreated in vivo with 20 mg/kg 3-nitropropionate, lambda(preconditioning onset) is 439.2 +/- 5.0 nm (p < 0.001 vs. control) in CA1 and 434.2 +/- 6.4 nm in CA3 (p < 0.001 vs. control; NS to lambda(preconditioning onset) in CA1). In controls, the fluorescence maximum shifts to lambda(control hypoxia) 458.2 +/- 1.3 nm in CA1 (NS vs. onset) and 456.0 +/- 3.6 nm in CA3 (NS vs. onset). On preconditioning with 3-nitropropionate, lambda(preconditioning hypoxia) shifts to 446.4 +/- 4.3 nm in CA1 (p < 0.03 vs. onset) and 438.6 +/- 6.9 nm in CA3 (p < 0.03 vs. onset). Posthypoxic decay of free and protein-bound NADH is diminished after preconditioning. We conclude that the free NADH level is reduced on an increase of hypoxic tolerance by chemical preconditioning. Reduction of free NADH content is maintained during hypoxia after preconditioning.
Huber
R
R
Department of Neurology, University of Ulm, Ulm, Germany.
Büchner
M
M
Li
H
H
Schlieter
M
M
Sperfeld
A D
AD
Speerfeld
A D
AD
Riepe
M W
MW
D000818:Animals; D015687:Cell Hypoxia; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006624:Hippocampus / Q000737:chemistry / Q000378:metabolism; D008297:Male; D051379:Mice; D009243:NAD / Q000032:analysis / Q000378:metabolism*; D009574:Nitro Compounds; D010085:Oxidative Phosphorylation / Q000187:drug effects*; D011422:Propionates / Q000494:pharmacology; D011485:Protein Binding; D013050:Spectrometry, Fluorescence; D013385:Succinate Dehydrogenase / Q000037:antagonists & inhibitors; D014018:Tissue Distribution
D004791:Enzyme Inhibitors; D009574:Nitro Compounds; D011422:Propionates; D009243:NAD; D013385:Succinate Dehydrogenase; C015392:3-nitropropionic acid